Loading
Lipidica
Lipidica is a Czech company developing a blood test that measures fats in the blood to look for pancreatic cancer in people at high risk. The test is being checked in a clinical study and is not an approved screening test.
Overview
Lipidica, a.s. is based in Pardubice, Czech Republic. Its LDPC (Lipidomics Diagnostic of Pancreatic Cancer) test analyses the lipid profile of plasma, and the investigational in vitro diagnostic software Lipidica 1.0 processes the results. The clinical performance study NCT06549725 aims to show whether the software can tell people with pancreatic cancer from those without it, in people at high risk through family history, selected gene mutations or hereditary pancreatic disease, alongside endoscopic ultrasound, MRI or CT and CA 19-9 and CEA tests. Its first registered cancer trial, NCT06549725, was posted on ClinicalTrials.gov in August 2024.
Notes
- Founding year not stated on the company website.
- No regulatory approval is claimed on the website; an image suggests ISO 13485 certification but this is not stated in text.
- No financing information found. Company website read on 29 October 2026.
Connected
4Similar pages
- CompanyCosomil
Shares High-risk pancreatic surveillance (CAPS / PRECEDE), Pancreatic ductal adenocarcinoma.
- Key paperPrecancerous neoplastic cells can move through the pancreatic ductal system
Shares High-risk pancreatic surveillance (CAPS / PRECEDE), Pancreatic ductal adenocarcinoma.
- Key paperRecommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium
Shares High-risk pancreatic surveillance (CAPS / PRECEDE), Pancreatic ductal adenocarcinoma.
- Key paperWhole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer
Shares High-risk pancreatic surveillance (CAPS / PRECEDE), Pancreatic ductal adenocarcinoma.
- Key paperDistant metastasis occurs late during the genetic evolution of pancreatic cancer
Shares High-risk pancreatic surveillance (CAPS / PRECEDE), Pancreatic ductal adenocarcinoma.
- InstitutionFred & Pamela Buffett Cancer Center
Shares High-risk pancreatic surveillance (CAPS / PRECEDE), Pancreatic ductal adenocarcinoma.
- TermPancreatic intraepithelial neoplasia (PanIN), the microscopic precursor of pancreatic cancer
Shares High-risk pancreatic surveillance (CAPS / PRECEDE), Pancreatic ductal adenocarcinoma.
- Key paperGenomic characterization of malignant progression in neoplastic pancreatic cysts
Shares High-risk pancreatic surveillance (CAPS / PRECEDE), Pancreatic ductal adenocarcinoma.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
lipidica.cz · 1
A source that has moved or gone is reported by the weekly link check. /audit/